Premium
Inflammatory Cytokines Presented from Polymer Matrices Differentially Generate and Activate DCs In Situ
Author(s) -
Ali Omar A.,
Tayalia Prakriti,
Shvartsman Dmitry,
Lewin Sarah,
Mooney David J.
Publication year - 2013
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201203859
Subject(s) - priming (agriculture) , cd86 , ccl20 , dendritic cell , immune system , immunology , t cell , cd80 , proinflammatory cytokine , cancer immunotherapy , immunotherapy , biology , cancer research , chemokine , microbiology and biotechnology , inflammation , cd40 , in vitro , cytotoxic t cell , chemokine receptor , biochemistry , botany , germination
During infection, inflammatory cytokines mobilize and activate dendritic cells (DCs), which are essential for efficacious T cell priming and immune responses that clear the infection. Here, macroporous poly(lactide‐ co ‐glycolide) (PLG) matrices are designed to release the inflammatory cytokines GM‐CSF, Flt3L, and CCL20 in order to mimic infection‐induced DC recruitment. The ability of these infection mimics to function as cancer vaccines is tested via induction of specific anti‐tumor T cell responses. All vaccine systems tested are able to confer specific anti‐tumor T cell responses and long‐term survival in a therapeutic B16‐F10 melanoma model. However, GM‐CSF and Flt3L vaccines result in similar survival rates and outperformed CCL20‐loaded scaffolds, even though they have differential effects on DC recruitment and generation. GM‐CSF signaling is identified as the most potent chemotactic factor for conventional DCs and significantly enhanced surface expression of MHC(II) and CD86(+), which are utilized for priming T cell immunity. In contrast, the use of Flt3L vaccines leads to greater numbers of plasmacytoid DCs, correlating with increased levels of T cell‐priming cytokines that amplify T cell responses. These results demonstrate that 3D polymer matrices modified to present inflammatory cytokines may be utilized to effectively mobilize and activate different DC subsets in vivo for immunotherapy.